Company intelligence / Profile preview

Glycart Biotechnology

Schlieren, Zurich, Switzerlandglycart.com ↗

Ownership: Private
Employees: ~180
Development stage: Commercial

Overview

Glycart developed the proprietary glycoengineering platform GlycoMAb®, which led to the creation of obinutuzumab (GA101), a next-generation anti-CD20 monoclonal antibody. Obinutuzumab was approved by the FDA as GAZYVA in 2013 under the Breakthrough Therapy designation. The company has contributed several other bispecific antibodies and immunomodulators now advancing through clinical development within Roche[2][3][5].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyNanobody therapy
Industry: Biotech

Partnerships

GenentechChugai Pharmaceuticals

Beyond the preview

Go deeper on Glycart Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycart Biotechnology.